Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction.

Journal: Cell

Published: 2020-10-29

DOI: 10.1016/j.cell.2020.09.015

Affiliations: 24

Authors: 36

Go to article
Institutions Share
Parker Institute for Cancer Immunotherapy, United States of America (USA) 0.27
Sage Bionetworks, United States of America (USA) 0.13
University of California, Los Angeles (UCLA), United States of America (USA) 0.11
Washington University in St. Louis (WUSTL), United States of America (USA) 0.08
Icahn School of Medicine at Mount Sinai (ISMMS), MSHS, United States of America (USA) 0.06
Division of Molecular Oncology and Immunology, Oncode Institute, Netherlands 0.06
Institute for Systems Biology (ISB), United States of America (USA) 0.04
Cancer Research Institute (CRI), United States of America (USA) 0.04
Fiona and Stanley Druckenmiller Center for Lung Cancer Research, MSKCC, United States of America (USA) 0.03
California Institute of Technology (Caltech), United States of America (USA) 0.03
Division of Vaccine Discovery, LJI, United States of America (USA) 0.03
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA) 0.02
Weill Cornell Medicine (WCM), Cornell University, United States of America (USA) 0.02
University of Pennsylvania (Penn), United States of America (USA) 0.01
University of Washington (UW), United States of America (USA) 0.01
Broad Institute of MIT and Harvard, United States of America (USA) 0.01
Cancer Center, MGH, United States of America (USA) 0.01
University of California, San Diego (UC San Diego), United States of America (USA) 0.01
Netherlands Cancer Institute (NKI), Netherlands 0.01
BioNTech US, United States of America (USA) 0.01

Return